Journal Article

Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection

Christopher Mullins, Geoffrey Eisen, Stephen Popper, Abdoulaye Dieng Sarr, Jean-Louis Sankalé, Judith J. Berger, Sharon B. Wright, Hernan R. Chang, Gérard Coste, Timothy P. Cooley, Peter Rice, Paul R. Skolnik, Margaret Sullivan and Phyllis J. Kanki

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 38, issue 12, pages 1771-1779
Published in print June 2004 | ISSN: 1058-4838
Published online June 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/421390
Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Human immunodeficiency virus type 2 (HIV-2), the second human retrovirus known to cause AIDS, is endemic to West Africa but is infrequently found outside this region. We present a case series of 10 HIV-2—infected individuals treated in the United States. Physicians applied the principles of highly active antiretroviral therapy (HAART), normally used in treating HIV type 1, with modifications considered appropriate for treating HIV-2. CD4+ cell count, HIV-2 virus load, and clinical status were found to correlate well, providing evidence that HIV-2 virus load is useful in managing treatment of patients with HIV-2 who are receiving therapy. However, HAART regimens with predicted efficacy for treatment of HIV type 1 infection are not as efficacious for treatment of HIV-2. Controlled clinical trials of HIV-2–infected patients receiving various HAART regimens are needed to provide therapeutic guidance to the medical community.

Journal Article.  4349 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.